Reduced cellular transport and activation of fluoropyrimidine nucleosides and resistance in human lymphocytic cell lines selected for arabinosylcytosine resistance.

[1]  P. Yo,et al.  Cross-resistance of dideoxycytidine-resistant cell lines to azidothymidine. , 1999, Biochemical pharmacology.

[2]  R. Agarwal,et al.  Collateral resistance of a dideoxycytidine-resistant cell line to 5-fluoro-2'-deoxyuridine. , 1999, Biochemical and biophysical research communications.

[3]  G. Peters,et al.  Common resistance mechanisms to deoxynucleoside analogues in variants of the human erythroleukaemic line K562 , 1999, British journal of haematology.

[4]  J. Mackey,et al.  Nucleoside transporters: molecular biology and implications for therapeutic development. , 1999, Molecular medicine today.

[5]  J. Mitsuhashi,et al.  Mechanisms for 5-fluorouracil resistance in human colon cancer DLD-1 cells. , 1998, Biological & pharmaceutical bulletin.

[6]  G. Peters,et al.  Comparison of 5-fluoro-2'-deoxyuridine with 5-fluorouracil and their role in the treatment of colorectal cancer. , 1998, European journal of cancer.

[7]  A. Krishan,et al.  Flow cytometric analysis of the multiple drug resistance phenotype , 1997, Leukemia.

[8]  M. Wientjes,et al.  Bladder tissue pharmacokinetics and antitumor effect of intravesical 5-fluorouridine. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[9]  D. Kerr,et al.  Hepatic arterial chemotherapy for metastatic colorectal carcinoma. , 1994, British Journal of Cancer.

[10]  J. R. Patton.  In vitro splicing of pre-messenger RNA with extracts from 5-fluorouridine-treated cells. , 1994, The Biochemical journal.

[11]  M. Yin,et al.  Isolation and characterization of a human ileocecal carcinoma cell line (HCT-8) subclone resistant to fluorodeoxyuridine. , 1993, Biochemical pharmacology.

[12]  Richie Jp.  Intravesical chemotherapy. Treatment selection, techniques, and results. , 1992 .

[13]  A. Sartorelli,et al.  RNA-directed actions of 5-fluorouridine in hemin stimulated K-562 erythroleukemia cells. , 1992, Cancer biochemistry biophysics.

[14]  P. Watkins,et al.  Rapid and efficient cloning of Alu-PCR products using uracil DNA glycosylase. , 1991, PCR methods and applications.

[15]  A. Mian,et al.  Thymidine and zidovudine metabolism in chronically zidovudine-exposed cells in vitro. , 1991, Biochemical pharmacology.

[16]  B. Oberg,et al.  Comparison of the substrate specificities of human thymidine kinase 1 and 2 and deoxycytidine kinase toward antiviral and cytostatic nucleoside analogs. , 1991, Biochemical and biophysical research communications.

[17]  L. Johnson,et al.  Thymidylate synthase overproduction and gene amplification in fluorodeoxyuridine-resistant human cells. , 1985, Molecular pharmacology.

[18]  K. Bhalla,et al.  Isolation and Characterization of a Deoxycytidine Kinase-deficient Human Promyelocyte Leukemic Cell Line Highly Resistant to 1-β-D- Arabinofuranosylcytosine , 1984 .

[19]  P. Danenberg,et al.  Human leukemic cells resistant to 5-fluoro-2'-deoxyuridine contain a thymidylate synthetase with lower affinity for nucleotides. , 1983, The Journal of biological chemistry.

[20]  H. Preisler,et al.  A pilot study of high-dose 1-beta-D-arabinofuranosylcytosine for acute leukemia and refractory lymphoma: clinical response and pharmacology. , 1982, Cancer research.

[21]  J. Wiley,et al.  Cytosine arabinoside influx and nucleoside transport sites in acute leukemia. , 1982, The Journal of clinical investigation.

[22]  D. Kufe,et al.  Correlation of cytotoxicity with incorporation of ara-C into DNA. , 1980, The Journal of biological chemistry.

[23]  R. McIvor,et al.  Facilitated transport of uracil and 5‐fluorouracil, and permeation of orotic acid into cultured mammalian cells , 1980, Journal of cellular physiology.

[24]  P. Danenberg.  Thymidylate synthetase - a target enzyme in cancer chemotherapy. , 1977, Biochimica et biophysica acta.

[25]  Y. Cheng,et al.  Human deoxycytidine kinase. Purification and characterization of the cytoplasmic and mitochondrial isozymes derived from blast cells of acute myelocytic leukemia patients. , 1977, Biochimica et biophysica acta.

[26]  D. Wilkinson,et al.  Metabolism of 5-fluorouracil in sensitive and resistant Novikoff hepatoma cells. , 1977, The Journal of biological chemistry.

[27]  R. Momparler,et al.  A model for the chemotherapy of acute leukemia with 1-beta-D-arabinofuranosylcytosine. , 1974, Cancer research.

[28]  C. Heidelberger,et al.  Thymidylate synthetase: mechanism of inhibition by 5-fluoro-2'-deoxyuridylate. , 1972, Biochemical and biophysical research communications.

[29]  J. Furth,et al.  Inhibition of Mammalian DNA Polymerase by the 5′-Triphosphate of 1-β-d-Arabinofuranosylcytosine and the 5′-Triphosphate of 9-β-d-Arabinofuranosyladenine , 1968 .

[30]  H. Skipper,et al.  Experimental evaluation of potential anticancer agents. XXI. Scheduling of arabinosylcytosine to take advantage of its S-phase specificity against leukemia cells. , 1967, Cancer chemotherapy reports.

[31]  T. Tong,et al.  Cancer statistics, 1994 , 1994, CA: a cancer journal for clinicians.

[32]  Y. Cheng,et al.  Metabolism and mechanism of action of 5-fluorouracil. , 1990, Pharmacology & therapeutics.

[33]  H. Tsutani,et al.  Transport and intracellular metabolism of fluorinated pyrimidines in cultured cell lines. , 1989, Advances in experimental medicine and biology.

[34]  Jackson Rc,et al.  Membrane transport alterations as a mechanism of resistance to anticancer agents. , 1986 .